Skip to main content
Top
Published in: Tumor Biology 11/2014

01-11-2014 | Research Article

Vitamin D inhibition of lung adenocarcinoma cell proliferation in vitro

Authors: Rong Li, Yuqing Lou, Weiyan Zhang, Qianggang Dong, Baohui Han

Published in: Tumor Biology | Issue 11/2014

Login to get access

Abstract

Vitamin D has the capability to inhibit tumor cell proliferation and promote tumor cell apoptosis but whether this mechanism exists in lung adenocarcinoma cells remains to be studied. Our objective is to explore whether vitamin D has the capability to inhibit lung adenocarcinoma cell proliferation and synergize with cisplatin. Our method was to explore the effect of different concentrations of 1,25(OH)2D3 with or without cisplatin on lung adenocarcinoma cells by detecting cell proliferation rates at different time points. 1,25(OH)2D3 was capsulated with nanomaterial before acting on lung adenocarcinoma cells, and cell proliferation rates at different time points were detected with the CCK-8 method. When vitamin D was applied at a concentration of 1 × 10−7 and 1 × 10−6 mol/L on A549, PC9, SPC-A1, and H1650 cells for 72 h, no inhibition occurred on cell proliferation. Between the concentrations of 1 × 10−5 and 0.5 × 10−5 mol/L, inhibition on cell proliferation increased with drug action time. Between the concentration of 2.5 × 10−5 and 0.03 × 10−5 mol/L, inhibition on cell proliferation increased with increasing drug concentration. Analysis using bivariate correlations showed that the correlation coefficient of the proliferation inhibition rate and drug content was 0.580 (p < 0.0001). The correlation coefficient of proliferation inhibition rate and the drug action time was 0.379 (p = 0.01). The combined use of vitamin D and dichlorodiammine-platinum(II) (DDP) significantly increased the inhibition rate on A549 cell proliferation, which peaked after culturing for 96 h (Table 4). Further analysis using bivariate correlations showed that the correlation coefficient between proliferation inhibition rate and DDP concentration was 0.319 (p < 0.0001). The correlation coefficient of the proliferation inhibition rate and vitamin D concentration was 0.269 (p < 0.0001). The correlation coefficient of proliferation inhibition and drug action time was 0.221(p = 0.003). Vitamin D capsulated with nanomaterial (5 ng/ml) on PC-9 cells for 72 h did not inhibit cell proliferation, while after 10 days, the content of crystal violet dissolved decreased by 6.3 ± 3.2 % for the nonleaded nanomaterial group and decreased by 45.8 ± 10.9 % for the nanomaterial-capsulated vitamin D group (p < 0.0001). Vitamin D has the capability to inhibit the proliferation of lung adenocarcinoma cells, synergistically inhibit the proliferation of lung adenocarcinoma cells with DDP, and when capsulated with nanomaterial can significantly inhibit the proliferation of lung adenocarcinoma cells.
Literature
1.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. Ca Cancer J Clin. 2009;59:225–49.PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. Ca Cancer J Clin. 2009;59:225–49.PubMedCrossRef
2.
go back to reference Cindy Davis D. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr. 2008;88(suppl):565S–9S.PubMed Cindy Davis D. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr. 2008;88(suppl):565S–9S.PubMed
3.
go back to reference Li R, Wu J, Xiong L, Han B. Lung cancer and benign lung diseases in patients with serious vitamin D deficiency in eastern China. Thoracic Cancer. 2012;3(4):303–6.CrossRef Li R, Wu J, Xiong L, Han B. Lung cancer and benign lung diseases in patients with serious vitamin D deficiency in eastern China. Thoracic Cancer. 2012;3(4):303–6.CrossRef
4.
go back to reference Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem. 2013;59(5):771–80.PubMedCrossRef Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem. 2013;59(5):771–80.PubMedCrossRef
5.
go back to reference Cheng TY, Neuhouser ML. Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient-nutrient interaction. Cancer Causes Control. 2012;23(9):1557–65.PubMedCrossRef Cheng TY, Neuhouser ML. Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient-nutrient interaction. Cancer Causes Control. 2012;23(9):1557–65.PubMedCrossRef
6.
go back to reference Ma Y, Yu WD, Hidalgo AA, Luo W, Delansorne R, Johnson CS, et al. Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle. 2013;12(5):743–52.PubMedCentralPubMedCrossRef Ma Y, Yu WD, Hidalgo AA, Luo W, Delansorne R, Johnson CS, et al. Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle. 2013;12(5):743–52.PubMedCentralPubMedCrossRef
7.
go back to reference Reungwetwattana T, Eadens MJ, Molina JR. Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy. Semin Respir Crit Care Med. 2011;32(1):78–93.PubMedCrossRef Reungwetwattana T, Eadens MJ, Molina JR. Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy. Semin Respir Crit Care Med. 2011;32(1):78–93.PubMedCrossRef
8.
go back to reference Ordóñez-Mena JM, Schöttker B, Haug U, Müller H, Köhrle J, Schomburg L, et al. Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large german prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2013;22(5):905–16.PubMedCrossRef Ordóñez-Mena JM, Schöttker B, Haug U, Müller H, Köhrle J, Schomburg L, et al. Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large german prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2013;22(5):905–16.PubMedCrossRef
9.
go back to reference Hossein-Nezhad A, Spira A, Holick MF. Influence of vitamin d status and vitamin d3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One. 2013;8(3):e58725.PubMedCentralPubMedCrossRef Hossein-Nezhad A, Spira A, Holick MF. Influence of vitamin d status and vitamin d3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One. 2013;8(3):e58725.PubMedCentralPubMedCrossRef
10.
go back to reference Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L. Vitamin D Receptor Genetic Variants are Associated With Chemotherapy Response and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2013. Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L. Vitamin D Receptor Genetic Variants are Associated With Chemotherapy Response and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2013.
11.
go back to reference Thyer L, Ward E, Smith R, Fiore MG, Magherini S, Branca JJ, et al. A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages. Nutrients. 2013;5(7):2577–89.PubMedCentralPubMedCrossRef Thyer L, Ward E, Smith R, Fiore MG, Magherini S, Branca JJ, et al. A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages. Nutrients. 2013;5(7):2577–89.PubMedCentralPubMedCrossRef
Metadata
Title
Vitamin D inhibition of lung adenocarcinoma cell proliferation in vitro
Authors
Rong Li
Yuqing Lou
Weiyan Zhang
Qianggang Dong
Baohui Han
Publication date
01-11-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1994-x

Other articles of this Issue 11/2014

Tumor Biology 11/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine